3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
2
Uveal Melanoma
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Multiple Myeloma
1
Interventions
Cyclophosphamide
14
Gemcitabine
6
Filgrastim
6
fludarabine
5
Methotrexate
5
Leucovorin
5
Granulocyte Colony-Stimulating Factor
5
Zoledronic Acid
4
Temozolomide
4
Mesna
4
Irinotecan
4
Ifosfamide
4
Etoposide
4
Cisplatin
4
Carboplatin
4
pembrolizumab
3
fludarabine phosphate
3
Doxorubicin
3
Biopsy
3
tanespimycin
2
poly ICLC
2
pegfilgrastim
2
lorukafusp alfa
2
liposomal doxorubicin
2
dinutuximab
2
cabozantinib
2
belinostat
2
Topotecan
2
Thalidomide
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Osteosarcoma
×
MAGEA3 protein, human
×
Clear all
NCT00944580
2017-11-24
A Vaccine Study for High Risk Cancers
Penn State University
Phase 1
Withdrawn